GlassScriptPhysician profile
Michael Spiegel
NPI 1033198817
$215,283.70
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111K · 2020: $40K · 2021: $14K · 2022: $30K · 2023: $21K · 2024: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Travel and Lodging: $1,242 · Food and Beverage: $701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,900.00 |
| Travel and Lodging | $1,241.77 |
| Food and Beverage | $700.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $76,296.04 | 2019-2023 | Taltz |
| Abbvie INC. | $63,905.68 | 2019-2024 | Skyrizi, Rinvoq |
| Ucb, INC. | $38,496.75 | 2019-2022 | |
| Radius Health, INC. | $15,890.16 | 2019-2022 | |
| Pfizer INC. | $14,205.45 | 2019-2023 | |
| Avion Pharmaceuticals | $5,657.50 | 2020 | |
| Amgen INC. | $493.72 | 2021-2024 | Evenity |
| Novartis Pharmaceuticals Corporation | $152.40 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $129.85 | 2022 | |
| Gilead Sciences, INC. | $56.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Spiegel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.